Literature DB >> 9766574

Characterization of p53 mutants identified in human tumors with a missense mutation in the tetramerization domain.

C Rollenhagen1, P Chène.   

Abstract

p53 is very often mutated in human cancers. The majority of alterations are missense mutations located within the DNA-binding domain of the protein. Many reports have characterized such mutant proteins. Little is known, however, about the properties of proteins that have a missense mutation outside this domain. We investigated here the properties of 8 mutant proteins identified in human tumors as having a missense mutation in the tetramerization domain. The Arg342Gln, Glu349Asp and Gln354Arg proteins behaved like wild-type both in vitro and in cells. Two mutants, Arg342Pro and Leu344Pro, were inactive in all assays. Finally, the 3 mutant proteins Leu330His, Arg337Cys and Arg337Leu, which are inactive in vitro, showed no activity at low expression levels in cells but became active at higher expression levels. Our results reveal new phenotypes for p53 mutants and suggest that sequencing of the p53 gene from patients with tumors should be extended to exons 9 and 10 in clinical investigations.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9766574     DOI: 10.1002/(SICI)1097-0215(19981029)78:3<372::AID-IJC19>3.0.CO;2-8

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  10 in total

1.  Cancer-associated p53 tetramerization domain mutants: quantitative analysis reveals a low threshold for tumor suppressor inactivation.

Authors:  Rui Kamada; Takao Nomura; Carl W Anderson; Kazuyasu Sakaguchi
Journal:  J Biol Chem       Date:  2010-10-26       Impact factor: 5.157

Review 2.  p53 functional assays: detecting p53 mutations in both the germline and in sporadic tumours.

Authors:  R S Camplejohn; J Rutherford
Journal:  Cell Prolif       Date:  2001-02       Impact factor: 6.831

3.  Parallel analysis of tetramerization domain mutants of the human p53 protein using PCR colonies.

Authors:  Joshua Merritt; Kim G Roberts; James A Butz; Jeremy S Edwards
Journal:  Genomic Med       Date:  2007-09-05

4.  p53 Tetramerization domain mutations: germline R342X and R342P, and somatic R337G identified in pediatric patients with Li-Fraumeni syndrome and a child with adrenocortical carcinoma.

Authors:  Lucja Fiszer-Maliszewska; Bernarda Kazanowska; Joanna Padzik
Journal:  Fam Cancer       Date:  2009       Impact factor: 2.375

5.  Further evidence for pathogenicity of the TP53 tetramerization domain mutation p.Arg342Pro in Li-Fraumeni syndrome.

Authors:  Anna Etzold; Julia C Schröder; Oliver Bartsch; Ulrich Zechner; Danuta Galetzka
Journal:  Fam Cancer       Date:  2015-03       Impact factor: 2.375

6.  Occurrence of multipolar mitoses and association with Aurora-A/-B kinases and p53 mutations in aneuploid esophageal carcinoma cells.

Authors:  Christiane D Fichter; Corinna Herz; Claudia Münch; Oliver G Opitz; Martin Werner; Silke Lassmann
Journal:  BMC Cell Biol       Date:  2011-04-06       Impact factor: 4.241

7.  Genetic analysis of rapidly progressing esophageal squamous cell carcinoma: A case report.

Authors:  Shuang Zhao; Ni Sun; Xi Yuan; Zetian Shen; Xixu Zhu; Jing Li
Journal:  Medicine (Baltimore)       Date:  2021-03-05       Impact factor: 1.817

8.  Noncanonical DNA motifs as transactivation targets by wild type and mutant p53.

Authors:  Jennifer J Jordan; Daniel Menendez; Alberto Inga; Maher Noureddine; Maher Nourredine; Douglas A Bell; Douglas Bell; Michael A Resnick
Journal:  PLoS Genet       Date:  2008-06-27       Impact factor: 5.917

Review 9.  p53 tetramerization: at the center of the dominant-negative effect of mutant p53.

Authors:  Jovanka Gencel-Augusto; Guillermina Lozano
Journal:  Genes Dev       Date:  2020-09-01       Impact factor: 11.361

10.  Colon cancer combined with obesity indicates improved survival- research on relevant mechanism.

Authors:  Zhou Yang; Xiyi Wei; Yitong Pan; Zhijun Min; Jingyuan Xu; Bo Yu
Journal:  Aging (Albany NY)       Date:  2020-11-10       Impact factor: 5.682

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.